NextCell Pharma AB (FRA:65G) Change In Receivables: €-0.05 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:65G NextCell Pharma AB FRA:65G
45 GF Score
Price €0.10
GF Value €0.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB Change In Receivables?

NextCell Pharma AB FRA:65G +31.27% 45 Change In Receivables is €-0.05 Mil as of Dec. 2025. GuruFocus rates FRA:65G with a GF Score™ of 45/100 and a GF Value™ of €0.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

NextCell Pharma AB's change in receivables for the quarter that ended in Dec. 2025 was €-0.01 Mil. It means NextCell Pharma AB's Accounts Receivable increased by €0.01 Mil from Aug. 2025 to Dec. 2025 .

NextCell Pharma AB's change in receivables for the fiscal year that ended in Aug. 2025 was €-0.16 Mil. It means NextCell Pharma AB's Accounts Receivable increased by €0.16 Mil from Aug. 2024 to Aug. 2025 .

NextCell Pharma AB's Accounts Receivable for the quarter that ended in Dec. 2025 was €0.28 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. NextCell Pharma AB's Days Sales Outstanding for the three months ended in Dec. 2025 was 157.31.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NextCell Pharma AB's liquidation value for the three months ended in Dec. 2025 was €1.39 Mil.

NextCell Pharma AB  (FRA:65G) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NextCell Pharma AB's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.281/0.163*91
=157.31

2. In Ben Graham's calculation of liquidation value, NextCell Pharma AB's accounts receivable are only considered to be worth 75% of book value:

NextCell Pharma AB's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2.392-1.224+0.75 * 0.281+0.5 * 0.03
=1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Change In Receivables Related Terms

NextCell Pharma AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Change In Receivables Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -0.15 -0.64 0.28 -0.16

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 0.09 -0.01 -0.13 -0.01
FRA:65G
45GF Score
NextCell Pharma AB FRA:65G
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-0.05 Mil mean?
NextCell Pharma AB (FRA:65G) has a Change In Receivables of €-0.05 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's Change In Receivables too high?
NextCell Pharma AB's current Change In Receivables is €-0.05 Mil. Overall, NextCell Pharma AB has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Change In Receivables compare to VRTX and REGN?
NextCell Pharma AB's Change In Receivables of €-0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for NextCell Pharma AB and its competitors. NextCell Pharma AB's current Change In Receivables is €-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.10 — trading 70% above its estimated fair value. The current Change In Receivables is €-0.05 Mil. NextCell Pharma AB's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Change In Receivables is €-0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of €0.10 is trading 70% above its estimated GF Value™ of €0.06. GuruFocus considers NextCell Pharma AB to be Significantly Overvalued.

Key valuation signals for FRA:65G:

  • Change In Receivables: €-0.05 Mil
  • GF Value™: €0.06 vs. price of €0.10 (70% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NextCell Pharma AB Business Description

Other Exchanges NXTCL:Sweden
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
45GF Score

Get the complete analysis for FRA:65G

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.06
GF Value